Ratings by Wells Fargo (Jim Birchenough)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/5/2026 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2025 | uniQure BV | QURE | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/2/2025 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2025 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/22/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2025 | Voyager Therapeutics | VYGR | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/12/2025 | Voyager Therapeutics | VYGR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/2/2025 | Sangamo BioSciences | SGMO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/31/2024 | Sangamo BioSciences | SGMO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/10/2024 | uniQure BV | QURE | Upgrade | Overweight (Equal Weight) |
7.30 (15.63) |
114.11% | Details | |
| 11/14/2024 | Sangamo BioSciences | SGMO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/7/2024 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | CRISPR Therapeutics | CRSP | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/8/2024 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2024 | CRISPR Therapeutics | CRSP | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/2/2024 | Voyager Therapeutics | VYGR | Upgrade | Overweight (Equal Weight) |
8.44 (3.90) |
-53.79% | Details | |
| 11/6/2023 | Sangamo BioSciences | SGMO | Downgrade | Equal Weight (Overweight) |
0.46 (0.38) |
-17.39% | Details | |
| 11/3/2023 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2023 | uniQure BV | QURE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/4/2023 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2023 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2023 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2022 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2022 | uniQure BV | QURE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/9/2022 | Global Blood Therapeutics | GBT | Downgrade | Equal Weight (Overweight) |
66.60 (68.49) |
2.84% | Details | |
| 2/9/2022 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2021 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2021 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2021 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/2/2021 | Tracon Pharmaceuticals | TCON | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/12/2021 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 12/7/2020 | CRISPR Therapeutics | CRSP | Downgrade | Equal Weight (Overweight) |
140.46 (56.50) |
-59.78% | Details | |
| 11/23/2020 | Moderna | MRNA | New Coverage | Equal Weight (N/A) |
97.61 (52.52) |
-46.19% | Details | |
| 11/17/2020 | Applied Genetic Technologies Corp. | AGTC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2020 | Tracon Pharmaceuticals | TCON | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/11/2020 | Five Prime Therapeutics | FPRX | Upgrade | Overweight (Equal Weight) |
5.49 (38.00) |
592.17% | Details | |
| 11/10/2020 | Voyager Therapeutics | VYGR | Downgrade | Equal Weight (Overweight) |
10.98 (3.90) |
-64.48% | Details | |
| 10/30/2020 | Bellicum Pharmaceuticals | BLCM | Downgrade | Equal Weight (Overweight) |
6.40 (0.62) |
-90.31% | Details | |
| 10/29/2020 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/15/2020 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/5/2020 | MyoKardia | MYOK | Downgrade | Equal Weight (Overweight) |
139.60 (224.91) |
61.11% | Details | |
| 8/31/2020 | Akcea Therapeutics, Inc. | AKCA | Downgrade | Equal Weight (Overweight) |
11.38 (18.17) |
59.67% | Details | |
| 8/19/2020 | Gilead Sciences | GILD | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/7/2020 | Principia Biopharma | PRNB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2020 | CRISPR Therapeutics | CRSP | Maintain | Overweight (N/A) |
|
Details | ||
| 6/25/2020 | uniQure BV | QURE | Downgrade | Equal Weight (Overweight) |
67.74 (14.27) |
-78.93% | Details | |
| 5/26/2020 | Regeneron Pharma | REGN | Upgrade | Overweight (Equal Weight) |
569.91 (759.86) |
33.33% | Details | |
| 5/18/2020 | IMV Inc. | IMV | Upgrade | Overweight (Equal Weight) |
2.30 (0.82) |
-64.35% | Details | |
| 4/20/2020 | Gilead Sciences | GILD | Downgrade | Equal Weight (Overweight) |
76.54 (143.93) |
88.05% | Details | |
| 3/19/2020 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2020 | Sunesis Pharmaceuticals Inc. | SNSS | Downgrade | Equal Weight (Overweight) |
0.97 (5.32) |
448.45% | Details | |
| 2/28/2020 | IMV Inc. | IMV | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/25/2020 | IMV Inc. | IMV | Downgrade | Equal Weight (Overweight) |
4.78 (2.30) |
-51.88% | Details | |
| 2/7/2020 | Principia Biopharma | PRNB | Maintain | Overweight (N/A) |
|
Details | ||
| 1/21/2020 | IMV Inc. | IMV | Upgrade | Overweight (Equal Weight) |
4.00 (4.78) |
19.5% | Details | |
| 1/15/2020 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2019 | Principia Biopharma | PRNB | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2019 | Fate Therapeutics | FATE | Upgrade | Overweight (Equal Weight) |
13.57 (1.33) |
-90.2% | Details | |
| 11/11/2019 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2019 | Celgene | CELG | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/28/2019 | IMV Inc. | IMV | New Coverage | Equal Weight (N/A) |
2.96 (0.82) |
-72.3% | Details | |
| 10/10/2019 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/7/2019 | Akcea Therapeutics, Inc. | AKCA | Upgrade | Overweight (Equal Weight) |
15.13 (11.38) |
-24.79% | Details | |
| 9/23/2019 | Akcea Therapeutics, Inc. | AKCA | New Coverage | Equal Weight (N/A) |
22.46 (15.13) |
-32.64% | Details | |
| 7/15/2019 | Gilead Sciences | GILD | Upgrade | Overweight (Equal Weight) |
66.19 (143.93) |
117.45% | Details | |
| 5/3/2019 | Intercept Pharmaceuticals | ICPT | Upgrade | Overweight (Equal Weight) |
85.82 (77.49) |
-9.71% | Details | |
| 4/22/2019 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2019 | Intercept Pharmaceuticals | ICPT | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/28/2019 | uniQure BV | QURE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2019 | Sangamo BioSciences | SGMO | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2018 | Tracon Pharmaceuticals | TCON | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/6/2018 | OncoMed Pharmaceuticals | OMED | Downgrade | Equal Weight (Overweight) |
1.11 (0.89) |
-19.82% | Details | |
| 12/3/2018 | Tesaro | TSRO | Downgrade | Equal Weight (Overweight) |
46.38 (74.96) |
61.62% | Details | |
| 10/31/2018 | Intercept Pharmaceuticals | ICPT | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/25/2018 | Celgene | CELG | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/10/2018 | CRISPR Therapeutics | CRSP | New Coverage | Overweight (N/A) |
36.56 (56.50) |
54.54% | Details | |
| 10/9/2018 | Principia Biopharma | PRNB | New Coverage | Overweight (N/A) |
26.37 (100.05) |
279.41% | Details | |
| 9/24/2018 | Applied Genetic Technologies Corp. | AGTC | Upgrade | Overweight (Equal Weight) |
4.40 (0.27) |
-93.86% | Details | |
| 9/4/2018 | Aeglea Biotherapeutics | AGLE | Downgrade | Equal Weight (Overweight) |
10.93 (12.01) |
9.88% | Details | |
| 8/28/2018 | Akcea Therapeutics, Inc. | AKCA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/28/2018 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (Overweight) |
|
Details |
